Starling Oncology (STLNW) Long-Term Investments (2020 - 2023)

Starling Oncology (STLNW) has reported Long-Term Investments for 4 consecutive years, with $58.9 million the latest figure, recorded in Q2 2023.

• For the quarter ending Q2 2023, Long-Term Investments changed N/A year-over-year to $58.9 million; the trailing twelve-month figure through Jun 2023 stood at $58.9 million (changed N/A YoY), and the FY2022 full-year result was $58.4 million, changed N/A from the prior year.
• Long-Term Investments was little changed at $58.9 million in Q2 2023 per STLNW's latest filing, from $58.8 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $230.3 million in Q1 2021 and bottomed at $58.2 million in Q3 2022.
• Historically, Long-Term Investments has averaged $161.5 million across 4 years, with a median of $230.0 million in 2021.
• The sharpest annual moves came in 2021 and 2022: Long-Term Investments fell 0.05% in 2021, then tumbled 74.69% in 2022.
• Over 4 years, Long-Term Investments stood at $230.3 million in 2020, then dropped by 0.1% to $230.0 million in 2021, then sank by 74.63% to $58.4 million in 2022, then climbed by 1.01% to $58.9 million in 2023.
• According to Business Quant data, Long-Term Investments over the past three periods registered $58.9 million, $58.8 million, and $58.4 million for Q2 2023, Q1 2023, and Q4 2022 respectively.